Sermorelin
Also known as: Geref
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of the 44-aa native hormone — the shortest fragment that retains full biological activity. It was FDA-approved in the 1990s as Geref (EMD Serono) for diagnostic testing of pituitary GH reserve and later for pediatric idiopathic GH deficiency, but was withdrawn from the US market in 2008–2009 at the manufacturer's request for commercial reasons (not safety or efficacy). It remains on the FDA Category 1 list of bulk substances nominated for use in 503A compounding, where it is now widely prescribed off-label for adult GH insufficiency and "anti-aging" indications.
Pricing for Sermorelin
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for Sermorelin
58 third-party tests across 17 vendors. Each card links to the full report.
For
Sermorelin
by Crush Research· batch CR-SMLN-10MG-2605-1
For
Sermorelin
by Peptide Supply Co.· batch SM1005192026
For
Sermorelin
by Real Peptides· batch Black Cap
For
Sermorelin
by NG Peptide· batch SM10-04
For
Sermorelin
by Reta Peptide· batch 20260409
For
Sermorelin
by OROS Research· batch OR-LPSERM5-426-B4
For
Sermorelin
by Ion Peptide· batch SERM10-03232026
For
Sermorelin
by Prime Peptides· batch 01222026SR
For
Sermorelin
by Licensed Peptides· batch SERMORE-01
For
Sermorelin
by Ion Peptide· batch SERM5-02022026
For
Sermorelin
by Ion Peptide· batch SRM10-01212026
For
Sermorelin
by Peptidegurus· batch 7th Jan,2026
For
Sermorelin
by Simple Peptide· batch SERM12292025-J
For
Sermorelin
by Real Peptides
For
Sermorelin
by Ion Peptide· batch SM10-12082025
For
Sermorelin
by Skye Peptides· batch SR25-10-002
For
Sermorelin
by Simple Peptide· batch SERM11202025-3
For
Sermorelin
by Ion Peptide· batch SR15-1125
For
Sermorelin
by Riptide Wellness· batch RWSER-10-1001
For
Sermorelin
by Reta Peptide
For
Sermorelin
by Reta Peptide
For
Sermorelin
by Ion Peptide· batch SRM10-1125
For
Sermorelin
by Ion Peptide· batch SR1-1025
For
Sermorelin
by Skye Peptides· batch SR25-05-002
29 citations indexed for Sermorelin
review · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
Study · 2026
Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance
Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration.
Study · 2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.
Study · 2026
A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review
The pursuit of pharmacological enhancement in sport has evolved from the widespread use of anabolic-androgenic steroids (AAS) to novel agents such as peptides and peptide analogues.
Study · 2026
Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry
Growth hormone-releasing hormone (GHRH) and its synthetic analogs are considered performance-enhancing substances and are therefore prohibited by the World Anti-Doping Agency (WADA).
review · 2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.